SMARCA2 and lung carcinoma: Miguel et al (2023) showed that resistance to tyrosine kinase inhibitors in lung cancer was mediated by up-regulation of SWI/SNF chromatin binding at downstream MAPK genes, which could be overcome using inhibition of the SWI/SNF subunits SMARCA2 and SMARCA460.